{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:03:56Z","timestamp":1779145436813,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Peking University People\u2019s Hospital Scientific Research Development Funds","award":["RDX2022-04 and RDJP2023-12"],"award-info":[{"award-number":["RDX2022-04 and RDJP2023-12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anticancer drug of tyrosine kinase-inhibitors (TKIs) has significantly improved the prognosis of patients with specific leukemia but has also increased the risk of organ adverse reactions. Herein, we present a case of a patient diagnosed with myeloproliferative neoplasms who experienced recurrent chest pain after receiving treatment with Olverembatinib. Electrocardiography and coronary angiography confirmed the diagnosis of myocardial infarction with non-obstructive coronary arteries. This case serves as a reminder for clinicians to pay more attention and actively prevent the cardiac adverse reactions of TKIs when using such medications.<\/jats:p>","DOI":"10.1186\/s12872-024-04011-w","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:03:41Z","timestamp":1719929021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapy and cardiovascular challenges: a case report of olverembatinib-induced myocardial infarction with non-obstructive coronary arteries"],"prefix":"10.1186","volume":"24","author":[{"given":"Haiyan","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"4944","key":"4011_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824\u201330.","journal-title":"Science"},{"issue":"21","key":"4011_CR2","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1182\/blood.V120.21.3749.3749","volume":"120","author":"D-W Kim","year":"2012","unstructured":"Kim D-W, Cortes JE, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. Efficacy and safety of Ponatinib according to prior approved tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia in chronic phase (CP-CML): results from the PACE trial. Blood. 2012;120(21):3749.","journal-title":"Blood"},{"issue":"4","key":"4011_CR3","first-page":"469","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S, Olverembatinib. First Approval Drugs. 2022;82(4):469\u201375.","journal-title":"First Approval Drugs"},{"issue":"1","key":"4011_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8(1):262.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"4011_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","volume":"18","author":"DJ Lenihan","year":"2013","unstructured":"Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18(8):900\u20138.","journal-title":"Oncologist"},{"issue":"15","key":"4011_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/eurheartj\/ehz054","volume":"40","author":"G Scalone","year":"2019","unstructured":"Scalone G, Mariani L, Aimi A, Grossi P. Coronary epicardic vasospasm in patient treated with desatinib for lymphoblastic leukaemia: the other side of the medal. Eur Heart J. 2019;40(15):1235.","journal-title":"Eur Heart J"},{"issue":"1","key":"4011_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12872-022-02504-0","volume":"22","author":"W Chen","year":"2022","unstructured":"Chen W, Du B, Liu K, Yu Z, Wang X, Yang P. Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review. BMC Cardiovasc Disord. 2022;22(1):46.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"4011_CR8","first-page":"330","volume":"76","author":"RB Fiets","year":"2018","unstructured":"Fiets RB, Staal AHJ, Cramer GE, Blijlevens NMA. Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia. Neth J Med. 2018;76(7):330\u20135.","journal-title":"Neth J Med"},{"issue":"3","key":"4011_CR9","first-page":"143","volume":"38","author":"S Agewall","year":"2017","unstructured":"Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143\u201353.","journal-title":"Eur Heart J"},{"key":"4011_CR10","first-page":"47","volume":"10","author":"M Slavich","year":"2016","unstructured":"Slavich M, Patel RS. Coronary artery spasm: current knowledge and residual uncertainties. Int J Cardiol Heart Vasc. 2016;10:47\u201353.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"4011_CR11","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","volume":"15","author":"RW van Leeuwen","year":"2014","unstructured":"van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315\u201326.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4011_CR12","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1097\/HJH.0000000000001805","volume":"36","author":"P Krishnamoorthy","year":"2018","unstructured":"Krishnamoorthy P, Gopalakrishnan A, Mittal V, Kalla A, Slipczuk L, Rangaswami J, et al. Gaisb\u00f6ck syndrome (polycythemia and hypertension) revisited: results from the national inpatient sample database. J Hypertens. 2018;36(12):2420\u20134.","journal-title":"J Hypertens"},{"issue":"2","key":"4011_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2337\/dc22-0783","volume":"46","author":"P Mone","year":"2023","unstructured":"Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F, et al. Stress hyperglycemia drives the risk of hospitalization for chest Pain in patients with ischemia and nonobstructive coronary arteries (INOCA). Diabetes Care. 2023;46(2):450\u20134.","journal-title":"Diabetes Care"},{"issue":"8","key":"4011_CR14","doi-asserted-by":"publisher","first-page":"105883","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105883","volume":"30","author":"B Kakadia","year":"2021","unstructured":"Kakadia B, Thakkar R, Sanborn E, Suero-Abreu GA, Jovin TG, Then R. Nilotinib-Associated atherosclerosis presenting as multifocal intracranial stenosis and Acute Stroke. J Stroke Cerebrovasc Dis. 2021;30(8):105883.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"4011_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533\u20139.","journal-title":"Am J Hematol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04011-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:05:12Z","timestamp":1719929112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04011-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4011"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04011-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained informed consent from the patient\u2019s son, who is authorized to make all medical related decisions on behalf of the patient through a legally binding power of attorney. This document was signed by both the patient and his son while the patient was fully conscious and competent, as assessed by our medical team. Therefore, the son, acting as the patient\u2019s legal representative, has agreed for the publication of the patient\u2019s information and images in an online open-access publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}